ReviewCancers2023
Optimal Management for Stage IVB Endometrial Cancer: A Systematic Review.
Review in Cancers, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
14 citing papers in PubMed, 12 citations in OpenAlex.
- Neoadjuvant Chemotherapy Followed by Interval Debulking for Advanced-Stage Endometrial Cancer: Survival Outcome Based on Surgical and Molecular Characteristics.Current oncology (Toronto, Ont.) · 2026Article
- Redefining the Treatment Landscape of Advanced Endometrial Cancer in the Era of Immunotherapy and Precision Oncology.Cancers · 2026Review
- Recurrent Distant Metastatic Endometrial Cancer Treated with Immunotherapy with Pembrolizumab: A Case Report and Literature Review.Diagnostics (Basel, Switzerland) · 2026Article
- Impact of peritoneal metastasis on overall survival in patients with advanced endometrial cancer receiving lenvatinib plus pembrolizumab.Discover oncology · 2026Article
- Neoadjuvant Chemotherapy Versus Primary Cytoreductive Surgery for Metastatic Endometrial Cancer.Cancer medicine · 2026Article
- Cannonball Metastases of the Lung: An Unusual Initial Manifestation of Endometrial Carcinoma.Respirology case reports · 2026Article
- The systemic immune-inflammation index in the efficacy prediction of neoadjuvant chemotherapy in patients with endometrial cancer.Translational cancer research · 2025Article
- Review
- Evaluating Treatment Strategies in Advanced Endometrial Cancer: Primary Cytoreductive Surgery Versus Neoadjuvant Chemotherapy Followed by Interval Debulking Surgery-A Ten-Year Single-Centre Experience.Obstetrics and gynecology international · 2025Article
- Survival benefit of cytoreductive surgery in patients with primary stage IV endometrial cancer: a systematic review & meta-analysis.BJC reports · 2024Article
- Surgery for Infrarenal Retroperitoneal Node Metastases from Colon Cancer.Journal of gastrointestinal cancer · 2024Article
- A retrospective study of anlotinib in patients with persistent, recurrent or metastatic cervical and endometrial cancer.Translational cancer research · 2024Article
- Article
- The immunological and prognostic significance of the diabetes mellitus-related gene WFS1 in endometrial cancer.Frontiers in immunology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
(1) Background: Endometrial cancer (EC) is a common gynecological malignancy, often diagnosed at an early stage with a high overall survival rate. Surgical treatment is the primary approach, guided by pathological and molecular characteristics. Stage IVB EC, characterized by intra and/or extra-abdominal metastasis, presents a significant challenge with no clear consensus on optimal management. (2) Methods: A systematic literature review was conducted from January to May 2023, covering studies from 2000 to 2023. Eligible studies included retrospective case series, prospective trials, and randomized clinical trials. (3) Results: Of 116 studies identified, 21 were deemed relevant: 7 on primary surgery, 10 on neoadjuvant chemotherapy (NACT), and 4 on adjuvant treatment. Notably, the impact of residual tumor after primary surgery was a critical factor affecting survival. The use of NACT followed by interval debulking surgery showed promise, particularly in cases deemed unresectable. Adjuvant treatment, combining radiotherapy and chemotherapy, demonstrated improved survival but lacked consensus regarding its role. (4) Conclusions: Stage IVB EC poses a complex challenge with limited evidence to guide management. Optimal cytoreduction remains crucial, and NACT should be considered for unresectable cases. Multimodality adjuvant therapy may benefit patients, even with disease spread beyond the pelvis. Future advances in molecular classification and targeted therapies are expected to enhance treatment strategies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.